Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

NCT06349837 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: Tislelizumab
RADIATION: Low Dose Radiotherapy
RADIATION: Stereotactic Ablative Radiotherapy

Sponsor

Sichuan University